Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer. It provides Kirsten RAT sarcoma virus (KRAS) and methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor programs.